Heijnsdijk EAM - Search Results - PubMed

This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Save citations to file

Email citations

Subject: Heijnsdijk EAM - PubMed

To:

From:

Selection:

Format:

MeSH and other data

Add to Collections

Add to My Bibliography

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

103 results

Page of 11

Results are displayed in a computed author sort order. The Results By Year timeline is not available.

Page 1

1

Cost-Effectiveness of Magnetic Resonance Imaging Screening for Women With Extremely Dense Breast Tissue.

Geuzinge HA, Bakker MF, Heijnsdijk EAM, van Ravesteyn NT, Veldhuis WB, Pijnappel RM, de Lange SV, Emaus MJ, Mann RM, Monninkhof EM, de Koekkoek-Doll PK, van Gils CH, de Koning HJ; DENSE trial study group. Geuzinge HA, et al. Among authors: heijnsdijk eam. J Natl Cancer Inst. 2021 Nov 2;113(11):1476-1483. doi: 10.1093/jnci/djab119. J Natl Cancer Inst. 2021. PMID: 34585249 Free PMC article.

2

Prostate-specific antigen screening in the United States vs in the European Randomized Study of Screening for Prostate Cancer-Rotterdam.

Wever EM, Draisma G, Heijnsdijk EA, Roobol MJ, Boer R, Otto SJ, de Koning HJ. Wever EM, et al. J Natl Cancer Inst. 2010 Mar 3;102(5):352-5. doi: 10.1093/jnci/djp533. Epub 2010 Feb 8. J Natl Cancer Inst. 2010. PMID: 20142584 Free PMC article.

3

Race-specific impact of natural history, mammography screening, and adjuvant treatment on breast cancer mortality rates in the United States.

van Ravesteyn NT, Schechter CB, Near AM, Heijnsdijk EA, Stoto MA, Draisma G, de Koning HJ, Mandelblatt JS. van Ravesteyn NT, et al. Cancer Epidemiol Biomarkers Prev. 2011 Jan;20(1):112-22. doi: 10.1158/1055-9965.EPI-10-0944. Epub 2010 Nov 30. Cancer Epidemiol Biomarkers Prev. 2011. PMID: 21119071 Free PMC article.

4

More on screening mammography.

van Ravesteyn NT, Heijnsdijk EA, de Koning HJ. van Ravesteyn NT, et al. N Engl J Med. 2011 Jan 20;364(3):282-3; author reply 285-6. doi: 10.1056/NEJMc1011881. N Engl J Med. 2011. PMID: 21247323 No abstract available.

5

How does early detection by screening affect disease progression? Modeling estimated benefits in prostate cancer screening.

Wever EM, Draisma G, Heijnsdijk EA, de Koning HJ. Wever EM, et al. Med Decis Making. 2011 Jul-Aug;31(4):550-8. doi: 10.1177/0272989X10396717. Epub 2011 Mar 15. Med Decis Making. 2011. PMID: 21406620 Free PMC article.

6

What if I don't treat my PSA-detected prostate cancer? Answers from three natural history models.

Gulati R, Wever EM, Tsodikov A, Penson DF, Inoue LY, Katcher J, Lee SY, Heijnsdijk EA, Draisma G, de Koning HJ, Etzioni R. Gulati R, et al. Cancer Epidemiol Biomarkers Prev. 2011 May;20(5):740-50. doi: 10.1158/1055-9965.EPI-10-0718. Cancer Epidemiol Biomarkers Prev. 2011. PMID: 21546365 Free PMC article.

7

Interpreting overdiagnosis estimates in population-based mammography screening.

de Gelder R, Heijnsdijk EA, van Ravesteyn NT, Fracheboud J, Draisma G, de Koning HJ. de Gelder R, et al. Epidemiol Rev. 2011;33(1):111-21. doi: 10.1093/epirev/mxr009. Epub 2011 Jun 27. Epidemiol Rev. 2011. PMID: 21709144 Free PMC article. Review.

8

Digital mammography screening: weighing reduced mortality against increased overdiagnosis.

de Gelder R, Fracheboud J, Heijnsdijk EA, den Heeten G, Verbeek AL, Broeders MJ, Draisma G, de Koning HJ. de Gelder R, et al. Prev Med. 2011 Sep;53(3):134-40. doi: 10.1016/j.ypmed.2011.06.009. Epub 2011 Jun 21. Prev Med. 2011. PMID: 21718717

9

The impact of PLCO control arm contamination on perceived PSA screening efficacy.

Gulati R, Tsodikov A, Wever EM, Mariotto AB, Heijnsdijk EA, Katcher J, de Koning HJ, Etzioni R. Gulati R, et al. Cancer Causes Control. 2012 Jun;23(6):827-35. doi: 10.1007/s10552-012-9951-8. Epub 2012 Apr 10. Cancer Causes Control. 2012. PMID: 22488488 Free PMC article. Clinical Trial.

10

Tipping the balance of benefits and harms to favor screening mammography starting at age 40 years: a comparative modeling study of risk.

van Ravesteyn NT, Miglioretti DL, Stout NK, Lee SJ, Schechter CB, Buist DS, Huang H, Heijnsdijk EA, Trentham-Dietz A, Alagoz O, Near AM, Kerlikowske K, Nelson HD, Mandelblatt JS, de Koning HJ. van Ravesteyn NT, et al. Ann Intern Med. 2012 May 1;156(9):609-17. doi: 10.7326/0003-4819-156-9-201205010-00002. Ann Intern Med. 2012. PMID: 22547470 Free PMC article.

103 results

Page of 11